Table 1.
The basic characteristics of the 16 RCT studies.
| Author/year | Groups | Sample size | Age (median or mean or range) | Course of disease | Course of treatment (days) | Intervention | Outcomes |
|---|---|---|---|---|---|---|---|
| Zhang et al., 2008 [16] | EP | 50 | 19–60 | 21.3 months | 28 | (1)+(2) | ①②③ |
| CG | 50 | 19–60 | 22.5 months | 28 | (1) | ||
| Jiang et al., 2009 [17] | EP | 32 | 18–52 | 6–24 weeks | 84 | (1)+(2) | ①②④ |
| CG | 30 | 18–50 | 6–25 weeks | 84 | (1) | ||
| Hu et al., 2011 [18] | EP | 28 | 21–58 | 9 weeks–11 months | 28 | (1)+(2) | ① |
| CG | 26 | 21–58 | 9 weeks–11 months | 28 | (1) | ||
| Cai, 2012 [19] | EP | 62 | 18–75 | 2 months–10 years | 40 | (1)+(2) | ①②③④ |
| CG | 58 | 18–75 | 2 months–10 years | 40 | (1) | ||
| Liang, 2012 [20] | EP | 60 | 34 ± 8.9 | 1.1 ± 0.25 years | 28 | (3)+(4) | ①②③ |
| CG | 60 | 36 ± 9.7 | 1.6 ± 0.5 years | 28 | (3) | ||
| Qu, 2013 [21] | EP | 43 | 12–45 | 6 weeks–2 years | 28 | (1)+(2) | ①② |
| CG | 43 | 13–43 | 6 weeks–2 years | 28 | (1) | ||
| Su et al., 2013 [22] | EP | 59 | 12–60 | ≥6 weeks | 28 | (3)+(4) | ①②③ |
| CG | 58 | 12–60 | ≥6 weeks | 28 | (3) | ||
| Wang, 2013 [23] | EP | 99 | 35–60 | 3 months–12 years | 28 | (1)+(2) | ①②③ |
| CG | 82 | 35–60 | 3 months–12 years | 28 | (1) | ||
| Wei and Zhang, 2013 [24] | EP | 41 | 34.5 ± 10.7 | ≥6 weeks | 28 | (3)+(2) | ①②③ |
| CG | 40 | 37.2 ± 12.9 | ≥6 weeks | 28 | (3) | ||
| Zhu, 2013 [25] | EP | 36 | 34.60 ± 4.20 | 2 months–3 years | 21 | (1)+(2) | ①②③ |
| CG | 28 | 34.60 ± 4.20 | 2 months–3 years | 21 | (1) | ||
| Xie, 2014 [26] | EP | 60 | 16–58 | 2 months–8 years | 56 | (1)+(2) | ①② |
| CG | 60 | 16–58 | 2 months–8 years | 56 | (1) | ||
| Fu et al., 2015 [27] | EP | 100 | 35.0 ± 3.0 | 4.1 ± 1.6 years | 56 | (3)+(4) | ①②③④⑤ |
| CG | 110 | 36.5 ± 2.5 | 4.4 ± 1.3 years | 56 | (3) | ||
| Li, 2015 [28] | EP | 62 | 18–56 | 2 months–3 years | 28 | (1)+(2) | ①② |
| CG | 48 | 20–58 | 2 months–4 years | 28 | (1) | ||
| Tian and Huang, 2015 [29] | EP | 86 | 18–62 | 8 weeks–5 years | 28 | (3)+(4) | ①②③⑤ |
| CG | 86 | 18–63 | 9 weeks–7 years | 28 | (3) | ||
| Qin et al., 2016 [30] | EP | 48 | 37.2 ± 9.5 | 1.0 ± 0.4 years | 28 | (3)+(4) | ①②③ |
| CG | 48 | 36.7 ± 8.6 | 1.2 ± 0.5 years | 28 | (3) | ||
| Zhao, 2016 [31] | EP | 35 | 39.25 ± 6.23 | 4.49 ± 2.26 years | 30 | (1)+(2) | ①②③④ |
| CG | 35 | 38.28 ± 7.23 | 3.65 ± 2.11 years | 30 | (1) |
(1) Desloratadine: 5 mg po qd; (2) Jade Screen: po tid + Desloratadine: 5 mg po qd; (3) desloratadine: 8.8 mg po qd; (4) Jade Screen: po tid + desloratadine: 8.8 mg po qd; EP: experiment group; CG: control group; ① total effective rate; ② adverse reaction; ③ recurrence rate; ④ symptom score; ⑤ serum IgE level.